FDA Approves Genentech's VABYSMO For Wet AMD And Diabetic Macular Edema - Food, Drugs, Healthcare, Life Sciences

On January 28, 2022, the Food and Drug Administration (FDA) approved Genentech's VABYSMO (faricimab-svoa) for the treatment of wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).

Related Keywords

,Genentech ,Drug Administration ,Mondaq ,Anti Vegf ,Approval ,Faricimab ,Fda ,Oche ,Food ,Drugs ,Healthcare ,Life Sciences ,Food And Drugs Law ,Iotechnology Amp Nanotechnology ,